Description
EORTC clinical research on the Gastrointestinal tract focuses on expanding what we know about the genetic, epigenetic and immunologic backgrounds of gastrointestinal tumour diseases. Clinical trials in this field focus on preclinical to clinical interaction and integrating early drug development, ensuring that new aspects of tumour biology are being investigated with appropriate contemporary technology.
The mission of the GI group is to develop therapeutic strategies through innovative studies, which are multidisciplinary, patient-centered and have a strong translational focus. It responds to the evolving landscape of cancer research by expanding its collaboration with different cancer research networks from Europe and Asia, enriching its pool of multidisciplinary experts and redesigning its young investigator’s program to enable future leaders to be at the forefront of GI cancer research.
Related News
All newsMain Achievements
- Several Task Forces of the Group were restructured to encourage greater activity and adapt to the virtual meeting environment:
- The Hepatobiliary, Pancreatic cancer, and Neuroendocrine tumours (NETs) Task Force was split into Hepatobiliary and NETs Task Force on one side, and Pancreatic cancer Task Force on the other, allowing for more focussed discussion groups.
- The Colorectal cancer and Anal & Rectal cancer Task Forces were merged in order to harmonise study proposal development.
- Out of 11 applicants to the 2021 call for applications, four Young and Early Career Investigators were selected for developing a research project with a grant from the GITCG.
- The publication reporting on early-onset colorectal cancer (Fontana E et al, JCO 2021) was selected for Rapid Communication in the Journal of Clinical Oncology.
Published joint Clinical Practice Guidelines on the management of hepatocellular carcinoma with the European Association for the Study of the Liver (EASL) ;
. These define the use of surveillance, diagnosis and therapeutic strategies recommended for patients with HCC.
The CLOCC randomised controlled phase II study performed in patients with liver metastases from colorectal cancer suggests that radiofrequency ablation of liver lesions prolongs survival . Based on these findings, the group is now starting a study combining this approach with immunotherapy (ILOC study).
Long-term follow up data in the EPOC randomised controlled phase III study confirm the significant improvement in progression-free survival of perioperative chemotherapy in resectable liver metastases from colorectal cancer.
Related Projects
European Reference Networks (ERN) for rare solid tumours (EURACAN). EURACAN is involving references centers in Europe covering ten types of rare cancers. EURACAN will improve patient cares and facilitate research in rare cancers. EORTC is providing the clinical research infrastructure. (No website available yet)
Research Group
Group documents-
Chair
Markus Moehler
Universitaetsmedizin der Johannes Gutenberg Universitaet Mainz-University Medical Center
Mainz, Germany
-
Secretary
Elisa Fontana
Sarah Cannon Research UK
London, United Kingdom
-
Treasurer
Manfred Lutz
CaritasKlinikum Saarbruecken St Theresia
Saarbrucken, Germany
-
Young Investigator Program
Hanneke van Laarhoven
Amsterdam UMC - locatie VUMC
Amsterdam, Netherlands
Task Force - Colon
-
M. Peeters - Antwerp, BE
Universitair Ziekenhuis Antwerpen
-
T. Kössler - Geneve, CH
Hôpitaux universitaires de Genève - HUG - site de Cluse-Roseraie
-
F. Sclafani - Brussels, BE
Institut Jules Bordet-Hopital Universitaire ULB
Task Force - Rectum, Anal canal
-
D. Arnold - Lisbon, PT
Hospital CUF Infante Santo
-
L. Wyrwicz - Warsaw, PL
Maria Sklodowska-Curie Memoral Cancer Center
Task Force - Esophagus and Stomach
-
E. Smyth - Cambridge, GB
Cambridge University Hospital NHS - Addenbrookes Hospital
-
A. Wagner - Lausanne, CH
Centre Hospitalier Universitaire Vaudois
Task Force - Hepatobiliary, Pancreas and NETs
-
J. Valle - Manchester, GB
The Christie NHS Foundation Trust
-
J. Ricke - Munich, DE
Kliniken Der Universitaet Muenchen
Task Force - Translational Research
-
H. Grabsch - Maastricht, NL
Academisch Ziekenhuis Maastricht
Task Force - SPECTA and early phase trials
-
R. Obermannova - Brno, CZ
Masaryk Memorial Cancer Institute
-
M. Alsina - Barcelona, ES
Vall d'Hebron Institut d'oncologia
Task Force - Adolescents and Young Adults
-
I. Ben-Aharon - Tel Aviv, IL
Rabin Medical Center - Tel Aviv University
Task Force - St. Gallen Meetings & Membership
-
M. Lutz - Saarbrucken, DE
CaritasKlinikum Saarbruecken St Theresia
Task Force - Young Investigator Program
-
H. van Laarhoven - Amsterdam, NL
Amsterdam UMC - locatie VUMC
-
M. Ducreux - Villejuif, FR
Institut Gustave Roussy
Task Force Newsletter
-
A. Elme - Tallinn, EE
North Estonia Medical Centre
Notable Publications
All publications on this research field-
2023
Associations of a Breast Cancer Polygenic Risk Score with Tumor Characteristics and Survival
-
2023
Patient-reported outcome measures for physical function in cancer patients: content comparison of the EORTC CAT Core, EORTC QLQ-C30, SF-36, FACT-G, and PROMIS measures using the International Classification of Functioning, Disability and Health
-
2022
Mitotic count is prognostic in IDH-mutant astrocytoma without homozygous deletion of CDKN2A/B. Results of consensus panel review of EORTC trials 26053 and EORTC 22033-26033
-
2022
The EORTC QLU-C10D – development and investigation of general population utility norms for Canada, France, Germany, Italy, Poland and the U.K.
-
2022
Relapse Patterns in early-PET negative, limited stage Hodgkin Lymphoma (HL) after ABVD with or without Radiotherapy – A joint analysis of the EORTC/FIL/LYSA H10 and NCRI RAPID Trials